atai Life Sciences Announces Fourth Quarter and Full Year 20

- Highlights included positive Phase 2b data with COMP360 from a ground-breaking treatment resistant depression (TRD) trial, highly encouraging Phase 2a proof-of-mechanism data with RL-007 in cognitive

Related Keywords

New York , United States , Ukraine , Boston , Massachusetts , San Diego , California , Berlin , Germany , London , City Of , United Kingdom , Camilla Dormer , Srinivas Rao , Otsuka Pharmaceuticals , Fellowship Fund In Psychedelic Neuroscience At Massachusetts , Recognify Life Sciences , Nasdaq , Hospital Center , Revixia Life Sciences , Exchange Commission , Multidisciplinary Association For Psychedelics Studies , Viridia Life Sciences , Life Sciences , Securities Exchange , Introspect Digital Therapeutics , Greg Weaver , Chief Financial Officer , Chief Scientific Officer , Florian Brand , Chief Executive Officer , Fellowship Fund , Psychedelic Neuroscience , Massachusetts General Hospital , Multidisciplinary Association , Psychedelics Studies , Resistant Depression , Depression Rating Scale , Investigational New Drug , Impairment Associated , Anxiety Disorder , Use Disorder , Traumatic Stress Disorder , Digital Therapeutics , Compass Pathways , Private Securities Litigation Reform Act , Securities Act , Securities Exchange Act , Annual Report , Jatai , Life , Ciences , Nnounces , Fourth , Quarter , Bull , Ear , 021 , Financial , Results , Reports , Progress , Highlights , Strategic , Focus , Areas , Nnovative , Ental , Health , Platform ,